The method presented is used by pharmaceutical regulatory authorities to detect data manipulation in clinical trials (bioequivalence). The code shown makes it possible to use the PK data of a clinical study to determine which blood samples may have been illegally reanalysed in order to positively influence the result of the study.
quality-assurance buster fraud bioequivalence clinical-trial re-analysis generic-drugs satowib pk-data
-
Updated
Dec 2, 2024 - R